Pacira Pharmaceuticals, Inc., together with its subsidiaries, operates as a specialty pharmaceutical company. The company focuses on the development, commercialization and manufacture of proprietary pharmaceutical products, based on its proprietary DepoFoam extended release drug delivery technology, primarily for use in hospitals and ambulatory surgery centers. In 2011, the United States Food and Drug Administration (FDA) approved its New Drug Application (NDA), for its primary product candidate, EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, and is an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for the company’s other FDA-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its other product candidates. The company plans to conduct Phase 3 studies for both upper and lower extremity nerve blocks, specifically a brachial plexus nerve block for patients undergoing total shoulder arthroplasty or rotator cuff repair and a femoral nerve block for patients undergoing total knee arthroplasty (TKA). The company’s product development activities utilize its proprietary DepoFoam drug delivery technology. DepoFoam consists of microscopic spherical particles composed of a honeycomb-like structure of various internal aqueous chambers containing an active drug ingredient. Each chamber is separated from adjacent chambers by lipid membranes. DepoCyt(e) is a sustained-release liposomal formulation of the chemotherapeutic agent cytarabine utilizing its DepoFoam technology. DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis, a life-threatening complication of lymphoma, a cancer of the immune system. Lymphomatous meningitis can be controlled with conventional cytarabine, but because of the drug’s short half-life, a spinal injection is required twice per week, whereas DepoCyt(e) is dosed once every two weeks in an outpatient setting. In 2015, the company announced two product candidates to its DepoFoam based pipeline: DepoMeloxicam (DepoMLX), and DepoTranexamic Acid (DepoTXA). The company’s preclinical product candidate, DepoMLX, is a long-acting non-steroidal anti-inflammatory drug (NSAID), designed to treat moderate to severe acute postsurgical pain as part of a non-opioid multimodal regimen. A product designed for single dose local administration, such as DepoMLX could provide a longer duration of pain relief at a significantly lower concentration of systemic NSAIDs, which are known to cause dose dependent gastrointestinal side effects. Meloxicam, which is available as an oral formulation, is a commonly used NSAID on the market today. DepoMLX is in pre-clinical development. Tranexamic Acid (TXA), is used off-label as a systemic injection or as a topical application, and is used to treat or prevent excessive blood loss during surgery by promoting hemostasis. DepoTXA is in pre-clinical development. Strategy The key elements of the company’s strategy include fully commercializing EXPAREL in the United States for postsurgical analgesia by infiltration; continuing to build and expand a streamlined commercial organization concentrating on major hospitals and ambulatory surgery centers in the United States and targeting surgeons, anesthesiologists, pharmacists and nurses; demonstrating the economic benefits of EXPAREL, working directly with managed care payers, quality improvement organizations, key opinion leaders, in the field of postsurgical pain management and leading influential hospitals in conducting Phase 4 retrospective and prospective trials and drug utilization evaluations; servicing and educating strategic commercial audiences for local infiltration procedures, including soft tissue, orthopedic, spine, anesthesia (such as infiltration into the transversus abdominis plane, or TAP block) and oral and maxillofacial surgeries, to ensure appropriate use of the product; obtaining FDA approval for additional indications for EXPAREL, including ner
pacira pharmaceuticals inc
5 Sylvan Way
Parsippany, NJ 07054
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for PCRX.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact PACIRA PHARMACEUTICALS INC, please visit www.pacira.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.